- Krka launches Robexera® injectable, a generic robenacoxib product in the UK
- COX-2 selective NSAID designed for perioperative pain and inflammation
- Fast onset within one hour and 24-hour duration of action
- Demonstrates strong safety profile, particularly in cats
- Provides cost-effective alternative to originator products
- Supports proactive pain management in surgical settings
Krka has expanded its veterinary NSAID portfolio with the UK launch of Robexera® 20 mg/ml injectable solution, marking the first generic robenacoxib injection available in the market.
The product is indicated for the targeted control of perioperative pain and inflammation in dogs and cats, offering veterinarians a more affordable alternative while maintaining the clinical benefits associated with the Robexera® range.
Targeted Pain Control with Rapid Action
Robexera® injectable is a highly COX-2 selective non-steroidal anti-inflammatory drug (NSAID), designed to minimize systemic effects while delivering effective pain relief. The injectable formulation provides rapid onset of action within one hour and sustained efficacy for up to 24 hours.
The therapy is particularly relevant in surgical settings, where timely and effective pain management is critical to recovery.
Strong Safety and Efficacy Profile
Clinical evidence highlights robenacoxib’s favorable safety profile, especially in feline patients, where perioperative use is common. Studies have also demonstrated its effectiveness in reducing post-operative pain, with reported advantages over meloxicam and evidence of anesthetic-sparing effects during surgery.
Supporting Proactive Pain Management
Veterinary guidelines increasingly emphasize proactive pain control to prevent complications such as central sensitization, which can make pain more difficult to manage post-surgery.
Krka noted that having access to a COX-2 selective injectable option allows veterinary teams to implement pre-emptive pain management protocols with greater confidence.
Expanding Access and Value
As a bioequivalent to the originator product, Robexera® injectable is positioned to deliver both clinical reliability and commercial value. The launch reflects growing demand for cost-effective therapeutics without compromising quality.
Krka, one of Europe’s largest generic pharmaceutical manufacturers, continues to expand its presence in the UK veterinary market with a portfolio focused on clinically proven, accessible treatments for companion and farm animals.
Information sourced from the company’s press release.
